References
- Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis and therapeutics. JAMA. 2011;305:391–399
- Pras E, Neumann R, Zandman-Goddard G, et al. Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum. 2004;34:602–609
- Levy RA, De Andrade FA, Foeldvari I. Cutting-edge issues in autoimmune uveitis. Clin Rev Allerg Immunol. 2011;41:214–233
- Theodossiadis PG, Lirakos VS, Sfikakis PP, et al. Intravitreal administration of the anti-TNF monoclonal antibody Infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol. 2009;247:273–281
- Giansanti F, Papucci L, Capaccioli S, et al. Ocular safety of Infliximab in rabbit and cell culture models. J Ocul Pharmacol Ther. 2010;26:65–71
- Farvardin M, Afarid M, Shahrzad S. Long-term effects of intravitreal Infliximab for treatment of sight threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther. 2012; 28:628–631
- De Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30:452–470
- Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophtalmol. 2007;18:481–486
- Gottemberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913–920
- Belkhou A, Younsi R, El Bouchti I, et al. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine. 2008;7:698–699
- Dasilva V, Breuil V, Chevallier P, et al. Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFα blockade: efficacy of rituximab, report of a single case. Joint Bone Spine. 2010;77:81–89
- Bomprezzi R, Pati S, Chansakul C, et al. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75:568–570
- Miserocchi E, Modorati G. Rituximab for non-infectious uveitis. Dev Ophthalmol. 2012;51:98–109
- Bargagli E, Olivieri C, Rottoli P. Cytokine modulators in the treatment of sarcoidosis. Rheumatol Int. 2011;31:1539–1544